Triple Incretin Receptor Agonist | GLP-1 + GIP + Glucagon for Advanced Fat Loss & Metabolic Optimization
Overview:
Retatrutide is a next-generation triple incretin agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and Glucagon receptors simultaneously. This unique triple-action mechanism offers a powerful blend of appetite suppression, fat oxidation, and energy regulation, positioning Retatrutide at the forefront of advanced weight management and metabolic enhancement therapies.
This product is supplied as a lyophilized powder and requires reconstitution before use.
Product Details
Triple Incretin Receptor Agonist | GLP-1 + GIP + Glucagon for Advanced Fat Loss & Metabolic Optimization
Overview:
Retatrutide is a next-generation triple incretin agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and Glucagon receptors simultaneously. This unique triple-action mechanism offers a powerful blend of appetite suppression, fat oxidation, and energy regulation, positioning Retatrutide at the forefront of advanced weight management and metabolic enhancement therapies.
This product is supplied as a lyophilized powder and requires reconstitution before use.
Why Choose Retatrutide 10mg (Single Vial)?
Retatrutide offers a more comprehensive metabolic approach by activating three complementary hormonal pathways instead of one or two.
Its compounded effects on appetite control, energy expenditure, and lipid metabolism make it an ideal option for individuals pursuing high-response, advanced fat-loss and body recomposition protocols.
Key Benefits
• Promotes deep, sustained fat loss through increased metabolic rate
• Strong appetite and craving suppression
• Enhances insulin sensitivity and glycemic control
• Supports lipid metabolism and energy balance
• Once-weekly subcutaneous dosing for convenience
Reconstitution Instructions
• Reconstitute using Bacteriostatic Water (BAC)
• Example: Add 2mL of BAC to a 5mg vial for a 2.5mg/mL solution
• Gently swirl (do not shake) until dissolved completely
• Store reconstituted Retatrutide in the refrigerator (2–8°C)
• Use within 28 days of reconstitution
Typical Dosing Guidelines
• Initial dose: start low (e.g., 0.25–0.5mg weekly)
• Therapeutic range: 1–5mg+ weekly, titrated based on tolerance and goal
• Administer via subcutaneous injection (abdomen, thigh, or upper arm)
• Duration: 12–24 weeks typical for significant body composition changes
Monitoring & Considerations:
• Common side effects: Nausea, fullness, slowed digestion, mild fatigue (usually temporary)
• Monitor: Blood glucose, hydration, GI tolerance, and lipid markers
• Contraindications: History of medullary thyroid carcinoma (MTC) or MEN2 syndromes
Note






Reviews
There are no reviews yet.